These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17675511)

  • 1. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.
    Li J; Song W; Czerwinski DK; Varghese B; Uematsu S; Akira S; Krieg AM; Levy R
    J Immunol; 2007 Aug; 179(4):2493-500. PubMed ID: 17675511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
    El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
    Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-κB activation.
    Arunkumar N; Liu C; Hang H; Song W
    Cell Mol Immunol; 2013 Jul; 10(4):360-72. PubMed ID: 23727784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
    Houot R; Levy R
    Blood; 2009 Apr; 113(15):3546-52. PubMed ID: 18941113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
    Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR ligands in the local treatment of established intracerebral murine gliomas.
    Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
    J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment.
    Ben Abdelwahed R; Cosette J; Donnou S; Crozet L; Ouakrim H; Fridman WH; Sautès-Fridman C; Mahjoub A; Fisson S
    J Exp Clin Cancer Res; 2013 Apr; 32(1):18. PubMed ID: 23561041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
    Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
    Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
    Nierkens S; den Brok MH; Garcia Z; Togher S; Wagenaars J; Wassink M; Boon L; Ruers TJ; Figdor CG; Schoenberger SP; Adema GJ; Janssen EM
    Cancer Res; 2011 Oct; 71(20):6428-37. PubMed ID: 21788345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.
    Ramaprakash H; Hogaboam CM
    Int Arch Allergy Immunol; 2010; 152(2):98-112. PubMed ID: 20016192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
    Krieg AM
    Curr Oncol Rep; 2004 Mar; 6(2):88-95. PubMed ID: 14751085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
    Weiner GJ
    Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of experimental asthma by mycobacterial protein combined with CpG requires a TLR9-dependent IFN-γ-CCR2 signalling circuit.
    Prado RQ; Bertolini TB; Piñeros AR; Gembre AF; Ramos SG; Silva CL; Borges MC; Bonato VL
    Clin Exp Allergy; 2015 Sep; 45(9):1459-71. PubMed ID: 25944185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
    Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
    Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
    J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.